The concentrations of proline, hydroxyproline, glycine and serine were determined in the plasma of 39 haemodialysis patients and 18 healthy subjects, using liquid chromatography with fluorescence detection. Plasma cpncentrations of the N-terminal immunoreactive parathyrin were also measured. In haemodialysis patients, the plasma concentrations of glycine (p < 0.01), hydroxyproline (p < 0.05) and proline (p < 0.10) were significantly increased, whereas the serine concentrations (p < 0.01) were decreased, compared with those of the healthy controls. Haemodialysis patients showed greatly elevated plasma N-terminal immunoreactive parathyrin valües (> 30 pmol/1), which showed a signiflcant correlation with the hydroxyproline values (r = 0.79). Fourteen haemodialysis patients received erythropoietin therapy. In these patients, changes in the concentrations öf plasma amino acids were observed up to one year after the beginning of therapy. In the course of the erythroppietin therapy, the plasma cöücentrations of glycine (p < 0.05) and hydroxyproline (p < 0.10) of the haemodialysis patients decreased, whereas the concentration of serine increased (p < 0.05) to approximately normal values. The resülts indicate that erythropoietin therapy leads to a normalization of amino acid metabolism.
Introduction
Osteodystrophies and elevated concentrations of hydroxyproline in plasma are closely correlated in patients with chrpnic renäl diseases. Hence, the concentration of free hydroxyproline in plasma was recom- A Fritz Lipmann dedicatory volume, originating frörn the Memorial Meeting held in Berlin-Dahlem in 1987, presenting the major aspects of modern biochemistry and their development in 90 essays. The Warburg/Meyerhof era, the time of emigration and postwar science are revived. Contemporaries and coworkers together with other outstanding scientists describe the state of biochemistry in major fields: äs it was, äs it is now, and where it will be göing. At the same time this volume is a reference book on Fritz Lipmann, the outstanding biochemist, and life scientist, who considered his concept of the energy-rich bond, symbolized by the squiggle, äs his major \ achievement. 
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Riedel et al,: Hydroxyproline, glycine and serine concentrations in plasraa of haemodialysis patients been shown experimentally (2) that hydroxyproline is the main biosynthetic precursor of serine in the proximal tubulus of the kidney. Glycine is an intermediate in the degradation of hydroxyproline, and it also serves s precursor of serine biosynthesis. Plasma concentrations of serine are usually lowered in uraemic patients (3, 4) . A disturbance of serine biosynthesis might therefore be reflected by an elevated concentration of plasma hydroxyproline, although other pathways of glycine and serine must be taken into consideration in making this Interpretation. Haemodialysis patients are normally anaemic. Some metabolic disturbances in haemodialysis patients are therefore closely related to their anaemia (5). This is in part accounted for by the reduced erythropoietin biosynthesis of the diseased kidney. The reduced osmotic resistance of erythrocytes in cases of elevated plasma concentrations of parathyrin might also contribute to anaemia (6) . Erythropoietin produced by genetic engineering techniques can now be sed to treat anaemia in haemodialysis patients. In the present study, we have determined aspartate, glycine, proline, hydroxyproline and serine in the plasma of haemodialysis patients and healthy subjects, and we have investigated the extent to which the disturbed metabolism of these mino acids in haemodialysis patients undergoing erythropoietin therapy can be infltienced by reducing anaemia.
Proline
Materials and Methods
Patients
Eighteen healthy subjects and 39 haemodialysis patients were included in the study. Fourteen of the haemodialysis patients were selected for erythropoietin therapy.
The control group included 6 male and 12 female persons from 21 to 56 years of age. The patient group included 15 men and 24 women from 21 to 76 years of age. Tne erythr poietin group included 2 men and 12 women from 26 to 76 years of age, who were suffering from nephronophthisis (n = 1), nephirosclerosis (n = 2), analgesia nephropathy (n = 4), glomerulonephritis (n = 3), nephrolithiasis with interstitial nephritis (n = 2) aiid chronic pyelonephritis (n = 2). The patients were haemodialysed 3 times a week for 4-5 hours over a period of 15 t 111 months. In the erythropoietin groupj the patients were injected intravenously with 100 U erythropoietin per kg body weight after each dialysis. When a h emoglobin concentration of 100 g/l was reached, the patients were maintained at this level by individual dose reduction. Before and in course pf erythropoietin therapy, all patients received phosphate lowering drugs if necessary. In course of the study 6 patients interrupted the therapy. With the consent of the patients, blood samples were collected by vein puncture in heparinized Sarstedt safety monovettes before dialysis. Recombinant human erythr poietin s freeze dried substance (BM 06.019) was a gift from Fa. Boehringer Mannheim GmbH.
Methods
Samples
Blood samples were centrifuged for 10 minutes at 3000g, and 200 μΐ plasma portions were immediately lyophilized and stored at -20°C.
Amino acid analysis
The following methods for amino acid analysis were pplied (T)· 1. Reagents and equipment Extraction buffer: 800 ml methanol H-200 ml 50 mmol/1 sodium acetate pH 7.0. Borate buffer: 0.5 mol/1 pH 9.5. Reagent I: 50 mg -phthaldialdehyde in 4.5 ml methanol, 500 μΐ borate buffer and 50 μΐ 2-mercaptpethanol. Reagent ίί: 50 mg -phthaldialdehyde in 4.5 ml methanol and 500 μΐ borate buffer. Eluent A: 220 ml methanol + 780 ml 50 mmol/1 sodium acetate pH 7.0. Eluent B: 750 ml methanol -i-250 ml 50 mmol/1 sodium acetate pH 7.0. Reagent III: 50 mg 7-chloro-4-nitrobenz-2-oxa-1.3-diazole in 5 ml methanol. The following HPLC equipment was used: Du Pont 850 System, Kontron fluorescence detector SFM 23, Lichrospher RP 18 (5 μπα) column (25 cm, 4.6 mm id.).
2. Serine, glycine, aspartate detennination Lyophilisates were extr cted with 1000 μΐ extraction buffer. Extracts (500 μΐ) were mixed with 200 μΐ borate buffer, 50 μΐ internal Standard (2 μg hofrioserine) and 100 μΐ reagent I. 3. Proline, hydroxyproline determination To the lyophilised plasma sample were added 500 μΐ extraction buffer, followed by vortexing then centrifugation for l minute at 3000 g. The extract (200 μΐ) was mixed wilh 100 μΐ borate buffer, 25 μΐ internal Standard (2 μΐ 3.4-dehydroproline) and 50 μΐ reagent II and incubated for l minute at 60 °C. Reagent III (50 μΐ) was added and the mixture was incubated for 5 minutes at 60 P C. After addition of 25 μΐ 2 mol/1 HC1 and l: 5 dilution with eluent A, 50 μΐ were injected onto the HPLC column.
Elution gradient conditions: 15 minutes 10-50% eluent B, exponent 2; 5 minutes 50-100% eluent B, linear. Detection: Excitation at 470 nm, emission at 530 nm.
The direct extraction of lyophilisates results in recoveries of amino acids up to nearly 100%. Coefficients of Variation for determination were (in series and from day to day, n = 5): serine 6.2%, 5.6%; glycine 7.0%, 8.2%; aspartate 4.6%, 8.6%; proline 3.4%, 2.5%, and hydroxyproline 2.7%, 2.4%.
Haemoglobin assay
Haemoglobin was determined s haemiglobin cyanide (Merckotest 3317, Fa. Merck). Intact parathyrin is present in normal plasma at a concentration of ~ 5 pmol/1. Plasma also contains biologically inactive fragments (mid-region-sequence 35-64 and C-region sequence 65 -84) at a ratio to intact parathyrin of 100:1. These inactive fragments cross-react with most parathyrin radioimmunoassays (8) . The N-Tact Parathyrid Hormone kit overcomes these obstacles by an extraction and concentration procedure using speciflc adsorption particles, which remove intact parathyrin and N-terminal-fragments. The correlation between biologically active parathyrin and the val-' ues determined with this kit is 95%.
Results
Haemodialysis patients showed elevated plasma concentrations f glycine, hydroxyproline and proline, and significantly lowered serine values, compared with the coiitrol group (tab. The success of the erythropoietin therapy can be monitored by the determination of blood haemoglobin (tab. 2). The desired haemoglobin content of 100 g/l was attained after approximately 12 weeks. In the 14 patients before erythropoietin therapy, plasma levels of N-terminal immunoreactive parathyrin were 22.9 ± 27.0 prnol/1. One year after the beginning of therapy the levels of N-terminal immunoreactive parathyrin wefe 14.2 + 10.6 pmol/1. The plasma levels of calcium, inorganic phosphate and alkaline phosphatase were slightly but not significantly increased duririg the course of the erythropoietin therapy (tab. 3).
Tab. 1. Free concentrations of amino acids in the plasma of healthy subjects (controls) and haemodialysis patients. Significance of t values by Studenfs t index p < 0.10 (*), p < 0.05 (**), p < 0.01 (***). Surprisingly, there is a significant increase in the plasma concentration of serine, and a simultaneous, significant drop in the glycine and hydroxyproline concentrations during the correction of the anaemia (tab. 4). The slightly elevated proline concentrations observed in haemodialysis patients ret rn to normal values after 12 weeks of erythropoietin therapy.
After one year of therapy the patient group was reduced to 8 patients. In this group, proline increased slightly and serine decreased slightly, compared with the values at 12 weeks, whereas hydroxyproline concentf ations decreased further to a normal level ( fig. 3 ).
Discussion
The occurrence of elevated glycine, hydroxyproline and proline concentrations s well s lowered serine concentrations in the plasma of patients with chronic renal disease has been known for some time (1> 3, 4, 10). However, the age^dependent increase of plasma levels of hydroxyproline should also be taken irito consideration. The control group in our study had a mean age of 42.4 +11.2 years, while the mean age of the patient group receiving erythropoietin therapy was 63.7 ± 13.4 years. Gilbertson et al. (11) have proposed a procedure for calculating the age-dependent normal plasma levels of total hydroxyproline (protein-bound + peptide-bound + free). In our study we have so far measured only the free hydroxyproline plasma levels. On the basis of the Gilbertson rule, for a median age difference of 21.3 years we should corr ect the total hydroxyproline plasma levels by about 6%. The differences between control and patient plasma levels of free hydroxyproline in our study were in the ränge of 144 äs to 36% ( fig. 3 ), i. e. far greater than the age-dependent differences.
A comparison of the plasma cpneentrations of hydroxyproline with those of parathyrin showed initially no correlation in the haemodialysis patients. However, the higher the parathyrin values, the more strongly they were corfelated ( fig. 2 ). According to Elevated hydroxyproline concentrations in plasma appear to be the result of metäbolic disturbances äs well äs the marker symptom of osteodystrophies. In addition, in patients suffering from renal failure, the impaired tubular reabsorption of amino acids must be considered. The unexpected drop in glycine, hydroxyproline and proline concentrations and the increase in serine concentrations towards a normalization of the amino acid level in course of the erythropoietin therapy suggests a correction of amino acid metabolism, including hydroxyproline. In the early phase of therapy (first 12 weeks), the decrease of plasma hydroxyproline concentrations showed a scatter (for Standard deviations, see tab. 4). After one year of therapy this scatter vanished, and the differences became significant.
Serine is mainly produced in liver and kidney from the pfecursor glycine, involving the enzyme serine hydroxymethylase 1 ) and the cofactor tetrahydrofolic acid (2) . During the depletion of the glycine pool, there is a simultaneous degradation of plasma hydroxyproline to produce more glycine. In an intermediate Step, transamination between 4-hydroxy-Lglutamate and oxalacetate produces 4-hydroxy-2-oxoglutarate and aspartate.
In the course of the erythropoietin therapy, the plasma concentrations of aspartate increase (p < 0.01). It is possible, however, that less hydroxyproline is produced during erythropoietin therapy, so that the reduction in hydroxyproline might indicate an improvement in the osteodystrophic Situation (see Varghese et al. (1)). Further evidence for this assumption seems to be the significant increase in the ratio, proline/ hydroxyproline, during the therapy. Measurements of calcium, inorganic phosphate and alkaline phosphatase showed no significant changes during erythropietin therapy. However, all patients received continuously phosphate lowering drugs, which influence these analytes. Hence this question cannot been settled on the basis of the plasma concentrations alone, but requires detailed biochemical investigations.
Doubtless the plasma concentrations of amino acids in haemodialysis patients during erythropoietin therapy might be influenced by dietary habits (4). The patients were informed about the necessity to eliminate such potential influences, and blood samples were taken in the morning after overnight fasting.
Nevertheless, in normal adult subjects who underwent starvation, the plasma concentrations of aspartate (-40%) and proline (-23%) were diminished, while those of glycine (+44%) and serine (+9%) were elevated (12)": In our haemodialysis patients, the plasma concentrations of aspartate (+169%), proline (+31%) and glycine (+62%) were elevated, while that of serine (-29%) was decreased. These values agree with reports of Chami et al. (14) and others. We shoiild expect an increase in the plasma levels of aspartate and proline and a decrease of glycine and serine äs positive nutritional effects. However, in our patients we see during the erythropoietin therapy an increase in aspartate, but a decrease in proline f and glycme, and an increase in serine, although after one year of therapy the trend towards the normalization of proline and serine is slightly reversed (fig. 3) , Hence the measured effects on amino acid metabolism in the coürse of erythropoietin therapy were orily partly explained by better nutrition. Without any doubt, however, determinations of amino acid plasma concentrations, which have been greatly facilitated and irnproved by the newly developed high pressure liquid Chromatographie fluorescence technique, will be of considerable help in monitoring the coürse of the disease and the therapy of haemodialysis patients.
